Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and Leukemia Group B trial 9342.
      Google Scholar   
Citation:
J Clin Oncol vol 22 (11) 2061-8
Year:
2004
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
Parents:
None
Children:
None
Program:
OGC
Primary Committee:
Breast
Sec. Committees:
   
Pharmas:
 
Grants:
CA03927, CA04457, CA07968, CA12046, CA21060, CA32291, CA33601, CA41287, CA47559, CA47577, CA60138, CA77406, CA77651  
Corr. Author:
 
Authors:
                                   
Networks:
 
Study
CALGB-9342
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords:
Adult, Antineoplastic Agents, Phytogenic, Breast Neoplasms, Disease-Free Survival, Dose-Response Relationship, Drug, Female, Humans, Logistic Models, Multivariate Analysis, Paclitaxel, Quality of Life, Survival Rate, Treatment Failure, United States